These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11113568)

  • 1. Opposite regulation of tenascin-C and tenascin-X in MeLiM swine heritable cutaneous malignant melanoma.
    Geffrotin C; Horak V; Créchet F; Tricaud Y; Lethias C; Vincent-Naulleau S; Vielh P
    Biochim Biophys Acta; 2000 Dec; 1524(2-3):196-202. PubMed ID: 11113568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation.
    Geffrotin C; Tricaud Y; Crechet F; Castelli M; Lefaix JL; Vaiman M
    Radiat Res; 1998 May; 149(5):472-81. PubMed ID: 9588358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenascin-C in primary malignant melanoma of the skin.
    Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
    Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription analysis in the MeLiM swine model identifies RACK1 as a potential marker of malignancy for human melanocytic proliferation.
    Egidy G; Julé S; Bossé P; Bernex F; Geffrotin C; Vincent-Naulleau S; Horak V; Sastre-Garau X; Panthier JJ
    Mol Cancer; 2008 Apr; 7():34. PubMed ID: 18442364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion.
    Kääriäinen E; Nummela P; Soikkeli J; Yin M; Lukk M; Jahkola T; Virolainen S; Ora A; Ukkonen E; Saksela O; Hölttä E
    J Pathol; 2006 Oct; 210(2):181-91. PubMed ID: 16924594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of tenascin in melanocytic tumours of dogs.
    Sevastre B; van Ederen AM; Terlou M; Gruys E; Nederbragt H
    J Comp Pathol; 2007 Jan; 136(1):49-56. PubMed ID: 17258226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
    Dang C; Gottschling M; Roewert J; Forschner T; Stockfleth E; Nindl I
    Br J Dermatol; 2006 Oct; 155(4):763-70. PubMed ID: 16965426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contact stimulation of fibroblasts for tenascin production by melanoma cells.
    Adám B; Tóth L; Pásti G; Balázs M; Adány R
    Melanoma Res; 2006 Oct; 16(5):385-91. PubMed ID: 17013087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenascin-C in primary Merkel cell carcinoma.
    Koljonen V; Jahkola T; Tukiainen E; Granroth G; Haglund C; Böhling T
    J Clin Pathol; 2005 Mar; 58(3):297-300. PubMed ID: 15735164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.
    Berndt A; Anger K; Richter P; Borsi L; Brack S; Silacci M; Franz M; Wunderlich H; Gajda M; Zardi L; Neri D; Kosmehl H
    J Cancer Res Clin Oncol; 2006 Aug; 132(8):537-46. PubMed ID: 16788848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma.
    Katenkamp K; Berndt A; Hindermann W; Wunderlich H; Haas KM; Borsi L; Zardi L; Kosmehl H
    J Pathol; 2004 Jul; 203(3):771-9. PubMed ID: 15221936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.
    Parekh K; Ramachandran S; Cooper J; Bigner D; Patterson A; Mohanakumar T
    Lung Cancer; 2005 Jan; 47(1):17-29. PubMed ID: 15603851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of melanoma-related microRNAs expression during the spontaneous regression of cutaneous melanomas in MeLiM pigs.
    Baco M; Chu CY; Bouet S; Rogel-Gaillard C; Bourneuf E; Le Provost F; Chu CY; Vincent-Naulleau S
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):668-70. PubMed ID: 24661544
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging molecular targets in melanoma invasion and metastasis.
    Orgaz JL; Sanz-Moreno V
    Pigment Cell Melanoma Res; 2013 Jan; 26(1):39-57. PubMed ID: 23095214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tenascin expression in melanocytic tumors.
    Tuominen H; Kallioinen M
    J Cutan Pathol; 1994 Oct; 21(5):424-9. PubMed ID: 7532653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling.
    Jones FS; Jones PL
    Dev Dyn; 2000 Jun; 218(2):235-59. PubMed ID: 10842355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma.
    Tseleni-Balafouta S; Gakiopoulou H; Fanourakis G; Voutsinas G; Balafoutas D; Patsouris E
    Exp Mol Pathol; 2006 Apr; 80(2):177-82. PubMed ID: 16259977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue Rebuilding During Spontaneous Regression of Melanoma in the Melanoma-bearing Libechov Minipig.
    Planska D; Kovalska J; Cizkova J; Horak V
    Anticancer Res; 2018 Aug; 38(8):4629-4636. PubMed ID: 30061229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
    Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
    Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.